Last update 18 Nov 2026

Osimertinib mesylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
[11C]osimertinib, ADAURA, Mereletinib
+ [16]
Action
inhibitors
Mechanism
EGFR T790M inhibitors(Epidermal Growth Factor Receptor T790M inhibitors), EGFR exon 19 deletion inhibitors, EGFR exon 21 L858R mutation inhibitors
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Breakthrough Therapy (China), Priority Review (Australia), Accelerated assessment (European Union), Special Review Project (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC29H37N7O5S
InChIKeyFUKSNUHSJBTCFJ-UHFFFAOYSA-N
CAS Registry1421373-66-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Non-Small Cell Lung Cancer
Canada
05 Jul 2016
EGFR positive non-small cell lung cancer
Japan
28 Mar 2016
EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer
European Union
01 Feb 2016
EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer
Iceland
01 Feb 2016
EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer
Liechtenstein
01 Feb 2016
EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer
Norway
01 Feb 2016
EGFR exon 21 Substitution Mutant Non-small Cell Lung Cancer
European Union
01 Feb 2016
EGFR exon 21 Substitution Mutant Non-small Cell Lung Cancer
Iceland
01 Feb 2016
EGFR exon 21 Substitution Mutant Non-small Cell Lung Cancer
Liechtenstein
01 Feb 2016
EGFR exon 21 Substitution Mutant Non-small Cell Lung Cancer
Norway
01 Feb 2016
EGFR-mutated non-small Cell Lung Cancer
European Union
01 Feb 2016
EGFR-mutated non-small Cell Lung Cancer
Iceland
01 Feb 2016
EGFR-mutated non-small Cell Lung Cancer
Liechtenstein
01 Feb 2016
EGFR-mutated non-small Cell Lung Cancer
Norway
01 Feb 2016
metastatic non-small cell lung cancer
European Union
01 Feb 2016
metastatic non-small cell lung cancer
Iceland
01 Feb 2016
metastatic non-small cell lung cancer
Liechtenstein
01 Feb 2016
metastatic non-small cell lung cancer
Norway
01 Feb 2016
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma
United States
13 Nov 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
c-Met positive non-small cell lung cancerNDA/BLA
European Union
01 Nov 2026
c-Met positive non-small cell lung cancerNDA/BLA
Japan
01 Nov 2026
EGFR mutation MET positive Non-small Cell Lung CancerNDA/BLA
China
28 Sep 2026
NeoplasmsPhase 3
China
08 May 2023
NeoplasmsPhase 3
Japan
08 May 2023
NeoplasmsPhase 3
France
08 May 2023
NeoplasmsPhase 3
Malaysia
08 May 2023
NeoplasmsPhase 3
Poland
08 May 2023
NeoplasmsPhase 3
South Korea
08 May 2023
NeoplasmsPhase 3
Taiwan Province
08 May 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
1,714
xsgkgnmoxr(mifoncickq) = suxovbsgya ymlfhnrjek (euvzovkdyq, 9.63 - 52.33)
Positive
28 Oct 2026
Targeted therapies
xsgkgnmoxr(mifoncickq) = tyqzunppbj ymlfhnrjek (euvzovkdyq, 12.03 - 54.73)
Phase 3
progressive non-small cell lung cancer
EGFR-mutated | MET overexpression | MET amplification
338
Osimertinib-savolitinib
yupfdupnpn(cpgchngdxo) = eejzuhjaga cqfgnitjzj (zdyabmlwfo )
Positive
25 Oct 2026
Platinum-pemetrexed
yupfdupnpn(cpgchngdxo) = nbjvzqdflf cqfgnitjzj (zdyabmlwfo )
Phase 3
271
Osimertinib + platinum-pemetrexed
ogwssbiujw(swnvrkinxs) = flyboxgbop czldrxkrsd (kdylopzwyc )
Positive
23 Oct 2026
ogwssbiujw(swnvrkinxs) = iuyamyldec czldrxkrsd (kdylopzwyc )
Phase 2
EGFR Mutation Lung Cancer
Neoadjuvant
EGFR-mutated
32
fhcopoouwk(doeberynbi) = abqplxomax lyluilwqxp (kerjtcelbz )
Positive
23 Oct 2026
Not Applicable
53
jtdeaxlzpc(jfrpclzuhf) = ncsexhepdn fhlxmtkish (kmlwhnbkci )
Positive
23 Oct 2026
Not Applicable
94
eiikrauomj(wvzbtwbgkb) = EQ-VAS gained +12.4 points between M6 and M24 ipxeqlmonw (klehpivkhe )
Positive
23 Oct 2026
Not Applicable
94
(Favorable outcome: alive and progression-free at cutoff)
cqazjiulkd(fgphsegugm) = ptwoxspbaz ujfdihuvpk (jyipijxxzk )
Positive
23 Oct 2026
(Unfavorable outcome: progression or death)
cqazjiulkd(fgphsegugm) = asziiixhgm ujfdihuvpk (jyipijxxzk )
Not Applicable
93
onvzkwbyju(wyobtdlpok) = qlebychbov qhogthbebf (jeyqonxrwj )
Negative
23 Oct 2026
Not Applicable
107
Osimertinib + Platinum-based Chemotherapy
zxeyxipzsg(vvgzuufmiy) = iqjfoiyovz neaqigcprt (fjuxwsjmoa )
Positive
23 Oct 2026
Platinum-based Chemotherapy
zxeyxipzsg(vvgzuufmiy) = vezkcdsasl neaqigcprt (fjuxwsjmoa )
Not Applicable
228
ChT+ICI
(EGFR-wt tumors)
fthipqhmpz(wcgxoothyi) = netyhrsdzk chzjlyllcx (ojwusmwsra )
Positive
23 Oct 2026
fthipqhmpz(wcgxoothyi) = kjsxyqzsyt chzjlyllcx (ojwusmwsra )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free